Drug Profile
Granisetron transdermal - Abeille Pharmaceuticals
Alternative Names: AB-1001; Granisetron transdermal - Abeille; Inno-P08002; SyB D-0701; SyB-0701Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Abeille Pharmaceuticals
- Developer Abeille Pharmaceuticals; INNOPHARMAX; SymBio Pharmaceuticals
- Class Analgesics; Antiemetics; Azabicyclo compounds; Indazoles; Small molecules
- Mechanism of Action Serotonin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chemotherapy-induced nausea and vomiting
- Phase II Radiotherapy-induced nausea and vomiting
Most Recent Events
- 06 Aug 2020 Kyowa Kirin withdraws a phase II trial in Gastroparesis in USA (Transdermal) due to limited resources (NCT04501211)
- 18 Apr 2016 ProStrakan is now called Kyowa Kirin International
- 01 Jun 2015 Phase III development is ongoing